Abstract:Fc-γ Receptors efficiently internalize antigen-antibodies (Ag-Ab) complexes and thus induce processing of antigens into peptides presented by MHC class II molecules. The recognition of p-MHC complex by T-cell receptor (TCR) trigger further immune reactions. It is still unclear how antigen binding in antibody and p-MHC binding in TCR communicate allosterically with their receptor bindings, respectively. The CDRs are responsible for Ag recognition, while the constant domains are crucial to activate effector function. To study the allosteric effects of antigen binding, we simulated four complex structures of free antibody, antigen bound antibody, FcR bound antibody, and antigen-antibody-FcR complex. As the conformation dynamics of antibodies are critical to antibody function, we chose 12 independent initial conformation to enhance the sampling. We reproduced experimental domain distribution density for the apo antibody, with the two Fabs move highly dynamic around the Fc region with Fab and Fc domains constantly forming and breaking contacts. When bind to antigen, the antibody conformation shift to two dominant conformation clusters, with one cluster has Fc-receptor binding site widely open. The final binding of Fc-γ Receptors leads to two conformation clusters, one corresponding to the antigen-free antibody-FcR baseline binding, and one for stronger antigen enhanced antibody-FcR interaction. Structural analysis of the antigen-antibody-FcR complex suggested that the antigen binding signal can transferred from the CDRs to the FcR by two main pathways, i.e. through hinge region and CH1/CL region. The results suggested that the stable contacts between CH1/CL and FcR is important for the transfer of antigen binding signals. Our study revealed the atomic mechanisms of the allosteric communications connection the antibody-antigen recognition and following FcR activation. During these processes, antigen binding shifts the antibody conformations which facilitate the FcR binding as well as allosteric signal transfer.

Architecture of the high-affinity immunoglobulin E receptor

Structural insights into the high-affinity IgE receptor FcεRI complex

Molecular Recognition of Fc-Specific Ligands Binding Onto the Consensus Binding Site of Igg: Insights from Molecular Simulation

Molecular mechanism of IgE-mediated FcεRI activation

High resolution mapping of mast cell membranes reveals primary and secondary domains of FcεRI and LAT

Revealed at last: Structure of the antibody-receptor complex common to all IgE-mediated allergic hypersensitivity reactions

Crystal Structure of the Ectodomain of Human FcαRI

Structural Insights into Immunoglobulin M

Molecular mechanism of IgM perception by IgM-specific receptor FcμR

Epidermal Langerhans Cells from Normal Human Skin Bind Monomeric IgE Via Fc Epsilon RI

Allosteric inhibition of IgE–FcεRI interactions by simultaneous targeting of IgE F(ab')2 epitopes

Identification of redundancy between human FcεRIβ and MS4A6A proteins points toward additional complex mechanisms for FcεRI trafficking and signaling

Contributions of F-BAR and SH2 Domains of Fes Protein Tyrosine Kinase for Coupling to the FcεRI Pathway in Mast Cells

A Co-Expressed Natural Antisense RNA FCER1A-AS Controls IgE-Dependent Immunity by Promoting Expression of FcεRIα

Structural similarity between Fc receptors and T cell receptors. Expression of the gamma-subunit of Fc epsilon RI in human T cells, natural killer cells and thymocytes.

Structure Of Fcry, An Avian Immunoglobulin Receptor Related To Mammalian Mannose Receptors, And Its Complex With Igy

Lipid-based and protein-based interactions synergize transmembrane signaling stimulated by antigen clustering of IgE receptors

Is Human IgE+ Equivalent to Mouse Highly Cytokinergic (HC) IgE?

Inhibition of IgE Activity to Bind Its High Affinity Receptor (fcεriα) by Mouse Anti-IgE Cε3∼4 Monoclonal Antibody (QME5).

Antigen Induced Dynamic Conformation Changes of Antibody to Facilitate Recognition of Fc Receptors

The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease